Skip to main content
OpenTrials
Completed

NCT Number: NCT05218213

Walking and Thinking - Brain Activity During Complex Walking in Aging and Parkinson's Disease

Every-day life means being part of a complex environment and performing complex tasks that usually involve a combination of motor and cognitive skills. However, the process of aging or the sequelae of neurological diseases such as Parkinson's disease (PD) compromises motor-cognitive interaction necessary for an independent lifestyle. While motor-cognitive performance has been identified as an important goal for sustained health across different clinical populations, little is known about underlying brain function leading to these difficulties and how to best target these motor-cognitive difficulties in the context of rehabilitation and exercise interventions.

The challenge of improving treatments of motor-cognitive difficulties (such as dual-tasking and navigation) is daunting, and an important step is arriving at a method that accurately portrays these impairments in an ecological valid state. The investigators aim therefore to explore brain function during complex walking in healthy and PD by investigating the effects of age and neurological disease on motor-cognitive performance and its neural correlates during three conditions of complex walking (dual-task walking, navigation and a combination of both) using non-invasive measures of brain activity (functional near infrared spectrometry, fNIRS) and advanced gait analysis in real time in young, older healthy adults and people with PD.

Completed

Looking for future studies?

Notify Me

Key information

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Healthy young:

Inclusion criteria

-18 to 50 years

Exclusion criteria

  • Disease or condition that affects cognition, gait or balance.
  • Severe hearing or visual impairments that affects participation in the assessments

Healthy elderly:

Inclusion criteria

  • ≥60 years of age,
  • 23 or more on the Montreal Cognitive Assessment (MoCA)

Exclusion criteria

  • Disease or condition that affects gait or balance.
  • Severe hearing or visual impairments that affects participation in the assessments

Parkinson cohort:

Inclusion criteria

  • ≥60 years of age
  • a clinical diagnosis of PD≤6 months prior to enrollment
  • with the ability to walk without a mobility device for ≤5 minutes continuously.

Exclusion criteria

  • People with speech difficulties (e.g. aphasia)
  • cognitive difficulties affecting the ability to understand and/or follow verbal/written - instructions
  • severe freezing of gait
  • Severe hearing or visual impairments that affects participation in the assessments
  • Other neurological diseases
  • Other disease that can affect gait or balance.

Treatment and study plan

No intervention

Other

Assessment of brain activity with fNIRS and behavioural assessments (motor, motor-cognitive and cognitive) during three complex walking conditions.

  • Dual-task walking with the auditory stroop task.
  • Navigational walking - a course consisting of a distribution of 45 and 90 degrees turns to the left and right
  • Navigational and dual-task walking (condition 1 and 2 together)

Primary outcomes

  1. Functional near infrared spectrometry (fNIRS)

    Time frame: During the test session during all three conditions

    The measurement of changes in concentration of HbO and HHb in the prefrontal cortex will be assessed using a NIRSPORT 2 (NIRx Medizintechnik, Berlin, Germany) device

  2. Gait performance during all conditions

    Time frame: During the test session during all three conditions

    Gait variables such as stride time and/or velocity will be analyzed with the APDM mobility system.

  3. Dual-task performance-reaction time

    Time frame: During the test session during dual task conditions

    Cognitive performance of the dual task will be assessed as errors in the response to the Auditory stroop task.

Secondary outcomes

  1. Cognitive function- composite score

    Time frame: During the test session, takes about 50 minutes

    The cognitive test battery comprised the following tests: The Color-Word Interference Test (CWIT), Verbal Fluency, Trail Making Test (TMT) and Ray Auditory Verbal Learning Test (RAVLT). Cognitive function will be assessed as a composite measure of these test together.

  2. Cognitive function - verbal fluency

    Time frame: During the test session, takes about 12 minutes

    Verbal function, initiation & task-set switching with the Verbal Fluency test from D-KEFS (Delis-Kaplan Executive Function System)

  3. Cognitive function - Attention and psychomotor processing speed

    Time frame: During the test session, takes about 3 minutes

    Attention and psychomotor processing speed will be assessed with the Trail Making Test (TMT) from D-KEFS (Delis-Kaplan Executive Function System)

  4. Cognitive function - Episodic memory

    Time frame: During the test session, takes about 30 minutes

    Episodic memory will be assessed with the Ray Auditory Verbal Learning Test (RAVLT).

  5. Cognitive function - Inhibition & task-set switching

    Time frame: During the test session, takes about 5 minutes

    Inhibition & task-set switching with the The Color-Word Interference Test (CWIT) from D-KEFS (Delis-Kaplan Executive Function System)

  6. Self-reported level of physical activity

    Time frame: Through study completion, an average of 1 year

    Assessed with the Frändin-Grimby Scale (score 1-6, higher score=better)

  7. Physical activity level and intensity

    Time frame: For one week after the test session

    Assessed with accelerometers (Actigraph GT3X+)

  8. Motor function/disease severity

    Time frame: During the test session

    Assessed with the movement Disorders Society- Unified Parkinson's Disease Rating Scale (MDS-UPDRS). Higher scores = worse/more symptoms

  9. Balance performance

    Time frame: During the test session

    Assessed with the Mini-BESTest (Balance Evaluation Systems test), 0-28p,

  10. Anxiety and depression

    Time frame: Will be answered before the test session in the patients home or during the test session

    Assessed with Hospital Anxiety and Depression Scale (HADS), 0-24 on the depression and anxiety part respectively. Lower score=better

  11. Walking ability

    Time frame: Will be answered before the test session in the patients home or at the test session

    Self assessed walking ability with the WALK-12G

  12. Dual-task performance -errors

    Time frame: During the test session during dual task conditions

    Cognitive performance of the dual task will be assessed as the reaction time to respond during Auditory stroop

  13. Disability

    Time frame: Will be answered before the test session in the patients home or during the test session

    WHO Disability Assessment Schedule (WHODAS) version 2.0, 12 self-assessed questions (12 to 60) more points=worse

Sponsors and collaborators

Lead sponsor

Karolinska Institutet

Other

Collaborators

  • Karolinska University Hospital

Registry information

Official study title

Walking and Thinking - Brain Activity During Complex Walking in Aging and Parkinson's Disease (Part of the ParkMOVE Trial)

Acronym: ParkMOVE

Important dates

Study start
2022
Primary completion
2023
Study completion
2023
First posted
Feb 1, 2022
Registry last updated
Oct 24, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.